its roles in growth-related signal transduction pathway, cell proliferation, apoptosis, and angiogenesis. [32] [33] [34] KLF6 is considered as a damage-response factor that promotes tissue remodeling because of its ability of transactivating several target genes by direct binding to their promoters. 19, 35 These genes comprise several members of the TGF-β signaling pathway such as TGF-β1, its receptors TβRI (ALK5) and TβRII, 36 the co-receptor endoglin (ENG), 37 urokinase-type plasminogen activator (uPA), 38 and collagen 1A (Col1A). 35 Furthermore, we have recently described a specific functional relationship between KLF6 and TGF-β pathway by the direct formation of a ternary Smad3-specificity protein 1 (Sp1)-KLF6 complex. 39 These effects suggest that KLF6 is a common regulatory factor for all the TGF-β functions related to injury, so KLF6 seems to orchestrate the repair mechanisms to return the endothelium to its regular state and to avoid the complications derived of its dysfunction. 40 In this article, we have explored the regulation of ALK1 expression under vascular injury. Our results demonstrate the transactivation of ALK1 gene by KLF6 and as a consequence the ALK1 upregulation in the migrating ECs. These data provide new insights in the molecular mechanisms mediated by KLF6 for the coordination of the vascular remodeling process and provide additional evidences for a pivotal role of ALK1 in the activated state of the EC during the angiogenic response after vascular injury.
Methods
Cell culture, 37, 41 expression vectors, 35, 42, 43 transfection and reporter assays, 41 stable infection of primary EC cultures, 44 real-time polymerase chain reaction, 41 in vitro EC denudation, 37 immunofluorescence microscopy, 37 flow cytometry, 37 immunohistochemistry, mechanical injury model in mouse femoral arteries, 45, 46 laser microdissection, and chromatin immunoprecipitation 41 are described in an expanded manner in the Material and Methods section of the Online Data Supplement.
Results

Alk1 Expression Is Increased In Vivo After Endothelial Injury
To assess the effect of vascular injury in vivo on Alk1 expression, we used a model of wire-induced endothelial injury in mouse. Mice were subjected to endothelial mechanical injury by using an angioplasty guidewire that removes the tunica intima of the hindlimb femoral artery. Then, the Alk1 expression levels post-injury were examined by immunohistochemistry after 4 weeks, when the proliferative response to arterial injury was prominent. 45, 46 At day 28, a clear hyperplasia of the neointima (NI), the new layer formed from inner elastic lamina, was detectable in the wounded area, as shown in Figure 1 . Alk1 expression was restricted to the endothelial single monolayer in uninjured femoral arteries. However, after injury, the hyperplasia was associated with a marked upregulation of Alk1 levels in the NI, and tunica media, which is composed mainly by vascular smooth muscle cells (vSMC). These results suggest a potential active role for Alk1 during vascular remodeling after an acute injury, in concordance with previous findings of the involvement of TGF-β pathway in the formation of the NI. 16 
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KLF6 Translocates to the Nucleus Before ALK1 Upregulation in Wounded ECs
The wounding effect on Alk1 expression was next assessed using a model of endothelial injury in vitro. To this end, monolayers of human umbilical vein ECs (HUVECs) were subjected to in vitro denudation, and ALK1 levels were measured by flow cytometry. As expected, ALK1 levels were upregulated 2 to 3 hours after injury, reaching a 5-fold increase after 24 hours ( Figure 2B ). To unravel the molecular mechanism underlying the ALK1 upregulation after wounding, KLF6, an early damage-response factor, was studied. After 3 hours, KLF6 translocation to the nucleus was observed by fluorescence microscopy (Figure 2A ). The translocation is restricted to cells adjacent to the wound, within 300 μm, and decreases in more distant areas (Online Figure I) . The nuclear localization of KLF6 is still evident after 8 hours, but at 24 hours, KLF6 has been shuttled back to the cytoplasm. In the same experiment, ALK1 surface levels underwent a time-dependent increase that peaked at 24 hours (5-fold upregulation), as measured by flow cytometry ( Figure 2B and 2C) . Moreover, the expression of ALK1 and KLF6 transcripts was analyzed by real-time polymerase chain reaction using total RNA from denuded HUVEC monolayers ( Figure 2D ). KLF6 mRNA levels were markedly upregulated, achieving a maximum of 6-fold induction after 2 hours, and these levels were slowly decreased reaching basal levels after 24 hours. A similar profile was observed with ALK1, whose mRNA levels were upregulated after 2 hours, returning to basal levels after 10 hours. This kinetics of ALK1 mRNA induction is compatible with the subsequent increase in ALK1 protein levels shown at the cell surface (after 12-24 hours). As a positive control, KLF6responsive ENG 37 showed a similar upregulation. As negative control, the levels of GAPDH were unaffected. Overall, these results demonstrate that on in vitro denudation of endothelial monolayers, KLF6 induction precedes ALK1 upregulation in ECs, and this kinetics is compatible with the transcriptional regulation of ALK1 by KLF6.
In Vivo Suppression of Klf6 Leads to Alk1 Downregulation
To assess the effect of Klf6 suppression in an in vivo model, Alk1 expression was studied in the liver of heterozygous Klf6 +/− mice. This organ was selected because HHT2 patients present a high prevalence of hepatic AVMs. 30 Total liver RNA from either Klf6 +/+ or Klf6 +/− mice was analyzed by real-time reverse transcription-polymerase chain reaction ( Figure 3A ). Levels of Klf6 mRNA in both 3-month and 6-month-old heterozygous mice were clearly diminished (≈60% compared with control values) with respect to their wild-type (WT) siblings. Interestingly, basal levels of Alk1 mRNA in Klf6 +/− heterozygous mice were expressed at lower levels than in WT animals. As a positive control, ENG levels were found to be decreased, although this reduction was more important in 6-month-old mice ( Figure 3A ). Further support for the Klf6-dependent regulation of Alk1 was obtained from protein staining in the vessel walls of these mice. Liver sections from Klf6 +/− heterozygous and their WT siblings were paraffinembedded and analyzed by immunohistochemistry ( Figure  3B ). In WT animals, Alk1 was clearly expressed in the endothelium of liver vessels. By contrast, Alk1 signal was much weaker in Klf6 +/− heterozygous mice. Furthermore, Alk1 staining of quiescent endothelium from femoral arteries was found to be lower in Klf6 +/− compared with Klf6 +/+ mice ( Figure 3C ). Also, on wire-induced endothelial injury, Alk1 protein was induced in both Klf6 +/+ and Klf6 +/− mice ( Figure  3C ), but laser microdissection studies showed that the upregulated Alk1 mRNA levels in Klf6 +/− were lower than in Klf6 +/+ animals ( Figure 3D ). In addition, a distinct vascular phenotype was observed ( Figure 3C and 3E). Thus, although the increase in the tunica media thickness was ≈2-fold in WT mice, only a slight augmentation (1.2-fold) was observed in Klf6 +/− mice. Remarkably, on injury, the NI of Klf6 +/+ mice was >2-fold thicker than that of Klf6 +/− animals. Taken together, these results agree with the crucial role of Alk1 in vascular remodeling and strongly support the involvement of Klf6 in the regulation of Alk1 gene expression.
ALK1 Gene Is a Transcriptional Target of KLF6
The experiments shown above suggest a transcriptional regulation of ALK1 by KLF6. Supporting this view, various consensus motifs for KLF6 were identified in the −1035/+210 fragment of the ALK1 promoter, at positions −815, −739, −148, −109, −86, and +150 ( Figure 4A ). The physical interaction between KLF6 and the ALK1 promoter was examined by chromatin immunoprecipitation. HUVEC monolayers were subjected to endothelial denudation, and chromatin immunoprecipitation experiments were assayed using an anti-KLF6 antibody both in control situation and after 3 hours of endothelial denudation. KLF6immunoprecipitated chromatin was subjected to polymerase chain reaction using 2 different couples of primers, encompassing the 2 clusters of KLF6 motifs present in the ALK1 promoter sequence. As shown in Figure 4A , KLF6 binding to ALK1 promoter was detected in both amplified fragments (−872/−670 and −208/+38) under basal conditions. Moreover, on endothelial wounding, the binding of KLF6 to ALK1 promoter was enhanced, as shown in the densitometric analysis ( Figure 4A ). This increase was especially evident in fragment −208/+38. These results indicate that, at least 1 KLF6 motif, within each cluster, is bound to KLF6 in vivo.
To assess the effect of this interaction, transcriptional experiments using ALK1 promoter (pALK1) constructs were performed. Transient transfections of the pGL2-pALK1 (−1035/+210) reporter vector with increasing doses of KLF6 resulted in a marked activation (up to 13-fold) of ALK1 promoter activity in human embryonic kidney 293T cells ( Figure 4B ). Moreover, using a KLF6-free cellular model such as Drosophila Schneider S2 cell line, a similar activation (up to 16-fold) of ALK1 promoter activity was obtained. Overall, these results show KLF6 binding to, and transactivation of, the ALK1 promoter. To assess the contribution of the different KLF6 motifs to ALK1 transcription, a set of deletion constructs of the ALK1 promoter was analyzed in human embryonic kidney 293T and Drosophila Schneider embryonic cells ( Figure 4C ). In both cell lines, the highest KLF6-induced response was obtained with the 2 largest constructs (−1035/+210 and −898/+50) containing 6 and 5 KLF6 binding motifs, respectively. The rest of the constructs (−587/+59, −422/+59, and −284/+59), all of them containing 3 KLF6 motifs, showed a proportional reduction in the KLF6-dependent transcriptional activity (≈50%) with respect to the largest constructs. These results demonstrate that KLF6 is able to interact with the −1035/+210 fragment of ALK1 promoter, stimulating its expression.
KLF6 Upregulates ALK1 Expression Through a Synergistic Cooperation With Sp1
Based on our previous work, where we demonstrated that ALK1 gene is Sp1-dependent for transcription initiation, 41 the transactivator effect of KLF6 on the ALK1 promoter segment −1035/+210 was assessed in the absence or presence of Sp1 in human embryonic kidney 293T cells. As expected, 41 Sp1 overexpression induced (≈4-fold) the transcriptional activity of the ALK1 promoter construct ( Figure 5A ). Similarly, overexpression of KLF6 achieved a 12-fold transactivating effect over the basal transcription rate of the ALK1 promoter. Interestingly, simultaneous overexpression of KLF6 and Sp1 allowed a maximum transactivating effect of ≈38-fold. Comparing the individual effects of Sp1 and KLF6 with the combined effect, it is obvious that the overexpression of both proteins leads to a clear synergistic cooperation, where the activating effect is much higher than the simple addition of each transcription factor independently. Next, the effect of both Sp1 and KLF6 overexpression on ALK1 protein levels was monitored by flow cytometry in ECs. As shown in Figure 5B , overexpression of Sp1 and KLF6 independently upregulated ALK1 protein at the cell surface. Single transfections of these factors in human microvascular ECs increased ALK1 expression between 1.2-and 2-fold for Sp1 and KLF6, respectively, whereas cotransfection experiments showed a clear cooperation between Sp1 and KLF6 reaching an upregulation of 4.5-fold. Similarly, single nucleofections of Sp1 and KLF6 in HUVECs increased ALK1 expression 2.6-and 1.7-fold, respectively, although no synergistic effect was detected, probably because of a cytotoxic/apoptotic effect of the combined treatment for 48 hours in these primary cells (data not shown).
Because ALK1 is involved in EC migration, 47-51 a hallmark of activated ECs, we analyzed whether the KLF6-dependent upregulation of the ALK1 protein was associated with a migratory phenotype. The human microvascular EC line-1 was transiently transfected with different combinations of Sp1 and KLF6 and then subjected to a wound healing assay. When both Sp1 and KLF6 are overexpressed in these ECs, their migration capacity was stimulated achieving the closure of the wound, after 24 hours ( Figure 5C ). The same type of experiment was performed with primary cultures of HUVECs, previously electroporated with Sp1 and KLF6 expression vectors (Online Figure II) , yielding a similar wound healing kinetics ( Figure 5C ). The toxicity derived from the Sp1/ KLF6 combination in HUVECs was not observed in this case because the migration studies were carried out within a short time frame (12 hours). Taken together, these data demonstrate that ALK1 is a KLF6 target gene and support the hypothesis that KLF6 acts cooperatively with Sp1 to promote endothelial activation of ALK1 during vascular remodeling.
KLF6 and Sp1 Knock Down Prevent ALK1 Upregulation During Wound Healing
The expression of Sp1 and KLF6, independently or in combination, was silenced in HUVECs, during the wounding process by transfection of specific small interfering RNAs (Online Figure III) . Figure 6A shows that silencing of Sp1, KLF6, or both resulted in the abolishment of the wound-mediated ALK1 induction as determined by flow cytometry analysis. When cellular migration was measured, as a function depending on ALK1 expression, in the presence of small interfering RNA of Sp1, KLF6, or both, HUVECs were unable to close the disrupted monolayer ( Figure 6B ) as compared with a correct healing when silencing was made with control scrambled small interfering RNA. These changes are shown in Figure  6C , where quantification of cell migration at each point time is expressed as number of migrated cells per field. These data corroborate that KLF6, in conjunction with Sp1, is essential for the upregulation of ALK1 during the angiogenic response to endothelial injury.
ALK5 Is Not Implicated in ALK1 Upregulation Induced by Vascular Injury
In ECs there are 2 TGF-β type I receptors, the ubiquitous ALK5 and the endothelial ALK1. Because a cross-talk between ALK1 and ALK5 has been postulated, 47, 50, 52 the possible role of ALK5 in the wound-induced ALK1 expression was assessed by measuring changes in ALK5 levels and activity. As shown in Figure  7A , ALK5 surface protein levels remained unchanged after wound healing, and the same was true for the corresponding mRNA levels ( Figure 7B ). To analyze the influence of ALK5 signal, ECs were treated with SB431542, a specific ALK5 kinase inhibitor. In spite of the suppression of ALK5 signaling, ALK1 expression was upregulated on wound healing, although at a slightly lower extent than cells treated with vehicle ( Figure  7C and 7D) . On scratching endothelial monolayers, the migration of cells is stimulated when the ALK5 pathway is inhibited ( Figure 7E ), whereas the ALK5 inhibitor stimulated the promoter activity of the Id1 target gene in ECs ( Figure 7F ). The efficiency of SB431542 treatment is demonstrated in HUVECs by the decrease in mRNA levels of PAI-1, a target gene of ALK5 (Online Figure IV) . These results suggest that whereas wound-mediated upregulation of ALK1 is mostly independent of the ALK5 signaling pathway, inhibition of ALK5 activity favors signaling through ALK1, as shown by the stimulation of cell migration and activation of the Id1 target.
ALK1 Is Upregulated in Smooth Muscle Cells After Wounding Through a Paracrine Communication With Endothelial Cells
As seen in Figure 1 , endothelial injury induces ALK1 upregulation in cells of the tunica media, suggesting the involvement of vSMC. As vSMCs are in close contact with ECs, we have explored the wounding effect in vSMCs. For this purpose, primary cultures of umbilical artery smooth muscle cells (UASMCs) were subjected to a scratching process and the surface levels of ALK1 were measured by flow cytometry. As observed in Figure 8A , UASMCs express high levels of ALK1 at their surface, but these levels remain unchanged along the wound healing process at variance with the increase of ALK1 in ECs after wounding. Accordingly, levels of ALK1 mRNA were unaffected ( Figure 8B) ; the same was true for KLF6, as opposed to the increased levels of KLF6 observed in ECs after wound healing ( Figure 2B-2D ). Staining of KLF6 in UASMC at different times after wound healing did not reveal any nuclear translocation either ( Figure 8C ), at variance to ECs, where nuclear translocation is evident after 3 hours ( Figure  2A) . Interestingly, when UASMCs were cultured with conditioned media from wounded monolayers of ECs, a significant increase in ALK1 was evident at mRNA and protein levels, already after 2 hours ( Figure 8D and 8E ). Furthermore, KLF6 mRNA levels were increased in parallel with ALK1 mRNA in UASMCs grown in conditioned media from ECs subjected to wound healing. The increase in ALK1 protein was sustained up to 24 hours ( Figure 8E ). Next, we assessed the contribution of the wound healing-dependent induction of KLF6 in ECs to the upregulated expression of ALK1 in UASMCs. KLF6 was overexpressed (using pCiNeo-KLF6) or suppressed (using pSuperKLF6) in HUVECs, and the corresponding conditioned media were used to culture vSMCs. As shown in Figure  8F , culture media from KLF6 overexpressing HUVECs induced a modest, but significant, increase (1.3-fold) in the expression levels of ALK1 of UASMCs. By contrast, culture media from HUVECs with a knocked down expression of KLF6-induced a marked reduction of ALK1 levels (0.6fold) compared with mock treated cells. Of note, changes in ALK1 levels paralleled those of KLF6 in vSMCs ( Figure 8G ). In summary, these results suggest that ALK1 is not directly upregulated in vSMCs in response to injury. Instead, endothelial injury triggers indirectly a similar KLF6-dependent stimulation of ALK1, in vSMCs. This response would constitute a paracrine mechanism operating from endothelium (intima) to smooth muscle cells (tunica media). In an attempt to analyze candidates responsible for this paracrine response, several cytokines and growth factors involved in angiogenesis were analyzed by ELISA in conditioned media from ECs after injury. The results showed a sustained increase of interleukin 6 (IL-6) in wounded cultures of HUVECs (from 6 to 24 hours after wounding; Online Figure VI ), suggesting the involvement of this cytokine in the upregulated expression of ALK1 in vSMCs after endothelial injury. To investigate the putative regulation of IL-6 by KLF6, immunohistochemistry staining of IL-6 in 4 weeks-injured femoral arteries from Klf6 +/− mice in comparison with WT littermates was carried out (Online Figure VIIA) . In uninjured vessels from WT and heterozygous animals, the presence of IL-6 was almost undetectable. By contrast, IL-6 staining was clearly detected on wire injury in different layers of the femoral artery. However, the increased signal of IL-6 in WT mice was higher than that of Klf6 +/− littermates, suggesting that KLF6 regulates IL-6 gene expression. Supporting this view, several putative consensus motifs for KLF6 were identified on in silico analysis of both human and mouse IL-6 proximal promoter sequences (Online Figure  VIII) . Furthermore, ectopic expression of KLF6 stimulated >3-fold the promoter activity of a luciferase reporter construct driven by the human IL-6 promoter sequence (Online Figure  VIIB) . Taken together, these experiments suggest that IL-6 is a target gene of KLF6. It can be speculated that KLF6 induction on vascular injury modulates the expression of a set of target genes, including IL-6, which in turn upregulate ALK1. An in-depth analysis of these genes may shed light on the molecular mechanism triggered to achieve vascular repair.
Discussion
ALK1 functions are closely related to vascular biology. 28, 53, 54 During embryogenesis, ALK1 is highly expressed in the vascular bed because of its critical requirement for a correct vasculogenic process, whereas in the adult life, the endothelium reaches quiescence and ALK1 expression levels drop. 24 In adults, the signaling network triggered by ALK1 is framed in the angiogenic process, when activated EC proliferate and migrate to develop new vessels from the preexistent ones, in response to certain stimuli. 23, 50 After formation of the new sprouts, a resolution phase is needed, in which TGF-β-mediated signaling blocks the proliferation and stabilizes the new vessel by the deposition of extracellular matrix. 47, 49 Therefore, TGF-β signaling in the EC during angiogenesis is crucial and needs to be highly regulated to control the balance between activating and resolving signals in each stage of the process. Having this in mind, a vascular damage would require an immediate ALK1 upregulation for the correct coordination of the subsequent repair mechanisms, whereas ALK5-controlled pathway should remain unchanged immediately after injury.
In HHT, patients harboring mutations in ALK1 are able to develop normal vessels, and their vascular system is, overall, indistinguishable from that of a healthy subject. However, when angiogenesis is activated in areas exposed to different stimuli, such as inflammation, injury, or hypoxia (second hit), ALK1 haploinsufficiency impairs the angiogenic process and may cause vascular lesions (telangiectases and AVMs), 55, 56 as it is frequently the case of nasal mucosa, where vessels suffer from mechanical injury. Therefore, identification of molecular mediators implicated in the response to vascular injury may provide new insights for understanding the mechanism involved in the formation of telangiectases and AVMs in HHT patients. In addition, this information may be useful to elucidate the molecular basis of vascular embolotherapy, a common method used to treat pulmonary AVMs in HHT patients that involves vascular damage and remodeling induced with coils or balloons. 56 Using both in vitro and in vivo models, we demonstrated that ALK1, but not ALK5, levels become strongly upregulated at the surface of ECs after vascular injury. We observed the existence of a temporal relationship between ALK1 upregulation and KLF6 translocation to the nucleus, in an in vitro endothelial wound healing model; a relationship that is compatible with a transcriptional involvement of KLF6 in ALK1 gene expression regulation. Supporting this observation, ALK1 protein and mRNA levels are much lower in liver vasculature and in femoral arteries of Klf6 +/− mice than those of WT animals, and ectopic expression of KLF6 is able to markedly transactivate the ALK1 promoter. Our recent studies on cloning and characterization of ALK1 gene promoter 41 prompted us to explore the potential regulation by KLF6 of the ALK1 gene. Based on the in silico analysis of the ALK1 promoter sequence, 6 putative consensus binding sites for KLF6 were found along the −1035/+210 pALK1 fragment. The motifs are located at positions −815, −739, −148, −109, −86, and +150. By chromatin immunoprecipitation we show that KLF6 indeed binds to the ALK1 promoter, and we demonstrate that, at least, 1 KLF6 motif is functional, within each one of the 2 KLF6 clusters located in −872/−670 and −208/+38, respectively. Of note, KLF6 binding to ALK1 promoter is evident under basal conditions, being this interaction increased after vascular injury. Remarkably, 3 of the KLF6 motifs are surrounding the major transcriptional start site (+1) driven by the transcription factor Sp1 through binding to the GC-rich regions in the TATA-less proximal promoter of ALK1. 41 These characteristics emphasize the importance of Sp1 in the basal mechanism of ALK1 transcription and explain the strong synergistic cooperation observed between KLF6 and Sp1 potentiating ALK1 transcriptional activity. Similarly, we have previously demonstrated the direct physical interaction and functional cooperation between Sp1 and KLF6 on the ENG promoter, in response to vascular injury. 37 There are also experimental evidences of similar regulatory mechanisms on the expression of other TGF-β family-related genes involved in vascular repair. 36, 37 Among them are TGF-β1, TβRI/ALK5, TβR-II, 36 as well as other important key regulators of the vascular physiology like Col1A 35 and uPA. 38 Of note, the transcriptional activation of uPA by KLF6 activates latent TGF-β1 in vascular ECs. 38 All these genes are intimately involved in endothelial homeostasis. Thus, even though KLF6 is ubiquitously expressed, after endothelium injury its endothelial expression is markedly increased, playing key roles in vascular biology. 34 Recently, we described the TGF-β regulation of KLF6 and its splice variants and the cooperative transactivation effect on common target genes through a Smad3/Sp1/KLF6 interaction, 39 highlighting the tight relationship between KLF6 and the TGF-β pathway. ALK1 and ENG are involved in a common signaling pathway within the TGF-β system, 22, 55, 56 in agreement with the fact that ALK1 and ENG gene mutations result in similar syndromic diseases, HHT2 and HHT1, respectively. 56 HHT is characterized by the presence of vascular lesions associated with fragile vessels and impaired vascular remodeling, likely a consequence of a deficient endothelial signaling in response to TGF-β. Indeed, experiments using heterozygous mouse models, alk1 +/− or eng +/− , have shown that vascular lesions develop on an angiogenic stimulus, such as vascular injury, because of an inappropriate EC wound-healing response. 23, 57 In this sense, ENG cooperates with ALK1 in the proliferating responses of ECs and opposes to ALK5promoted responses, including growth arrest, differentiation of ECs, recruitment of pericytes, and production of extracellular matrix proteins. 50, 52 The signal(s) that triggers the KLF6 nuclear translocation remains to be elucidated. It can be postulated that the loss of intercellular contacts sustained by VE-cadherins and integrins might be a primary stimulus for KLF6 translocation in ECs affected by the wound. This nuclear translocation would promote an immediate stimulation of KLF6 target genes, including ENG, ALK1, and KLF6 itself, to start the repair process. In the context of vascular homeostasis after endothelial damage, crucial players are the vSMCs in close contact with the EC layer, contributing to vessel stabilization and recovery. Alk1 is highly expressed in the vSMC layers surrounding the tunica intima as seen in Figure 1 , and it is especially conspicuous in the process of NI formation after femoral denudation. At variance with ECs, neither ALK1 upregulation nor KLF6 translocation in cultured vSMCs was observed on direct wounding. Thus, a cross-talk between endothelial and smooth muscle cell layers appears necessary for a correct homeostasis of the vessel wall. Indeed, in vitro experiments have shown that ALK1 is induced in vSMCs through a paracrine signal from the wounded endothelium. In this regard, the increase of IL-6 along the wounding process of ECs suggests that this factor is a putative candidate to contribute to the paracrine effect on vSMCs surrounding the endothelium. Thus, the release of soluble factors, such as IL-6, from the injured endothelium would serve to expand the repair signal by upregulating ALK1 from the inner to the more distant layers of the vessel. In addition, among the soluble factors secreted in vivo, it would be worth analyzing the levels of BMP-9, a specific ligand for ALK1 and ENG. [58] [59] [60] BMP-9 is synthesized by the liver, circulates in human adult blood, is involved in vascular remodeling, and induces vascular quiescence. 15, 61 However, the in vitro effects of BMP-9 on endothelial proliferation and migration are controversial, as some reports have described an inhibition, whereas others have described a stimulation of these functions. 58, 59, 62 Because EC proliferation and migration are increased on vascular injury, it will be of interest to find out whether the upregulation of ALK1 and ENG in this setting is associated with changes in BMP-9 levels.
Overall, the parallelism between ALK1 and ENG in their pathophysiological functions as well as in their regulated gene expression in response to endothelial damage supports their involvement in the TGF-β-dependent events triggered by a vascular injury to recover the endothelial homeostasis. Because haploinsufficiency is the mechanism of pathogenicity in HHT1 and HHT2, 56, 63 those stimuli able to upregulate the gene expression of ALK1 and ENG constitute therapeutic targets to counteract the haploinsufficiency. In this regard, the characterization of KLF6 as a mediator of vascular injury in the induction of ALK1 and ENG expression deserves an independent investigation.
